CASI CASI Pharmaceuticals, Inc.: Total Company Value-to-Revenue Ratio

CASI Pharmaceuticals Inc. (CASI) - corporate logo

Steady cash flow for CASI Pharmaceuticals (CASI) is driven by the sales of onay drugs in China. The company's EV/Sales ratio exhibits local dynamics, with the current metric standing at 0.00. Business growth relies on adapting Western molecules to PRC regulations and the strategic licensing of innovative blood therapies, which guarantees significant pricing power within the onco-hematology segment.

CASI CASI Pharmaceuticals, Inc.: Company Value to Revenue in the range 11/23/2025 - 03/14/2026

CASI Pharmaceuticals, Inc. - analytical breakdowns and key metrics (CASI)

- current quotes and average value forecast:
- company stock capitalization data:
Fundamental company valuation:CASI - CASI Pharmaceuticals, Inc
Brand item of casipharmaceuticals.com

This indicator compares the total enterprise value to sales volume, excluding the impact of debt load to identify the real market valuation of generated cash flows. Analyzing the enterprise value-to-revenue multiple allows for an assessment of the commercial oncology ecosystem efficiency of CASI Pharmaceuticals (CASI) in China, determining the extent to which the market capitalizes on the company's role as a key distributor of Western pharmaceuticals.